Not Signed In - Repeated Radioimmunotherapy With 131I-Labetuzumab In Colorectal Cancer With Liver Metastases Found Safe And Well-Tolerated In Initial Phase II Study
Sat, 03 Jun 2006 06:00 AM EST
... Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonalantibodies, today reported that repeated use of its radiolabeled antibodyagainst the carcinoembryonic antigen (CEA), 131I-labetuzumab, has beenfound to be safe and well-tolerated by patients with colorectal cancer thathas metastasized to the liver. [click link for full article] ...
Related Topics
- Colorectal Cancer
- Liver Cancer
- Metastatic Cancer
- Clinical Trials
- Liver Disease
- Cancers
- Rectal Cancer
- Liver Biopsy
- Kidney Cancer
- Pancreatic Cancer
- Thyroid Cancer
- Childhood Cancers
- Cancer, Colorectal
- Colorectal Cancer, Childhood
- Hereditary nonpolyposis colorectal cancer
- Hepatocellular
- Childhood Liver Cancer
- Liver Cancer, Childhood
- Small Intestine Cancer
- Bile Duct Cancer
email this page
print this page
bookmark this page
feedback on this page
